Also trades as: SUVENPHAR.NS (NSE) · $vol 3M
SUVENPHAR.BO BSE
Suven Pharmaceuticals Limited
1W: +0.3%
1M: -4.4%
3M: -13.6%
1Y: +61.1%
3Y: +71.2%
5Y: +626.3%
₹1,075.30
Last traded 2025-06-10 — delisted
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$30.3B
+34.5% ▲
5Y CAGR: +20.9%
Total Liabilities
$11.9B
+485.5% ▲
5Y CAGR: +29.4%
Shareholders Equity
$17.0B
-17.3% ▼
5Y CAGR: +15.0%
Cash & Investments
$2.9B
-64.6% ▼
5Y CAGR: +47.0%
Total Debt
$2.8B
+329.4% ▲
5Y CAGR: +8.4%
Net Debt
$1.9B
+990.2% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $72M | $446M | $648M | $472M | $854M |
| Short-Term Investments | $1.8B | $4.8B | $4.2B | $7.7B | $2.1B |
| Cash & ST Investments | $1.9B | $5.3B | $4.9B | $8.2B | $2.9B |
| Net Receivables | $1.0B | $2.4B | $1.1B | $1.3B | $2.8B |
| Inventory | $2.0B | $2.8B | $3.1B | $2.3B | $1.7B |
| Other Current Assets | $575M | $594M | $772M | $709M | $1.5B |
| Total Current Assets | $5.6B | $11.3B | $10.1B | $12.6B | $8.9B |
| Property, Plant & Equip. | $5.3B | $5.6B | $7.7B | $7.9B | $12.5B |
| Goodwill & Intangibles | $26M | $22M | $622M | $619M | $7.2B |
| Long-Term Investments | $3.6B | $1.2B | $1.2B | $1.3B | $1.4B |
| Other Non-Current Assets | $60M | -$1K | $33M | $116M | $286M |
| Total Non-Current Assets | $9.1B | $7.0B | $9.5B | $9.9B | $21.4B |
| Total Assets | $14.7B | $18.3B | $19.7B | $22.5B | $30.3B |
| — Liabilities — | |||||
| Accounts Payable | $726M | $1.1B | $488M | $424M | $802M |
| Short-Term Debt | $1.1B | $671M | $646M | $386M | $719M |
| Deferred Revenue | $279M | $341M | $256M | $2M | $0 |
| Other Current Liabilities | $103M | $22M | $235M | $119M | $1.8B |
| Total Current Liabilities | $2.2B | $2.1B | $1.6B | $1.1B | $3.7B |
| Long-Term Debt | $356M | $284M | $46M | $0 | $62M |
| Other Non-Current Liab. | $376M | $632M | $665M | $105M | $5.6B |
| Total Non-Current Liabilities | $739M | $921M | $718M | $965M | $8.3B |
| Total Liabilities | $2.9B | $3.0B | $2.3B | $2.0B | $11.9B |
| — Equity — | |||||
| Common Stock | $255M | $255M | $255M | $255M | $255M |
| Retained Earnings | $9.4B | $12.7B | $14.7B | $17.7B | $15.1B |
| Accumulated OCI | $1.1B | $1.2B | $1.3B | $1.5B | $533M |
| Total Stockholders Equity | $11.8B | $15.3B | $17.4B | $20.5B | $17.0B |
| Total Liabilities & Equity | $14.7B | $18.3B | $19.7B | $22.5B | $30.3B |
| — Key Metrics — | |||||
| Total Debt | $1.4B | $971M | $703M | $650M | $2.8B |
| Net Debt | $1.4B | $526M | $55M | $178M | $1.9B |
| Total Investments | $3.6B | $1.2B | $1.2B | $9.0B | $3.5B |